76.80CHF-0.52%Mkt Cap: 5.76B CHFP/E: 38.79Last update: 2026-05-13
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)38.79
P/E (Forward)24.92
PEG0.61
P/B3.87
P/S8.12
EV/EBITDA26.93
EV/Revenue8.17
EPS (TTM)1.98
EPS (Forward)3.02
Cash Flow & Leverage
FCF Yield-1.32%
FCF Margin-10.90%
Operating CF271.57M CHF
CapEx (TTM)329.40M CHF
Net Debt/EBITDA0.14
Net Debt29.28M CHF
Technical
SMA 5066.98 (+14.7%)
SMA 20062.06 (+23.7%)
Beta0.78
S&P 52W Chg24.23%
Avg Vol (30d)145.96K
Avg Vol (10d)174.88K
Technical Indicators
RSI (14)62.0
MACD3.4346
MACD Signal3.0480
MACD Hist.+0.3867
BB Upper82.62 CHF
BB Middle72.86 CHF
BB Lower63.09 CHF
BB Width26.81%
ATR (14)2.875 CHF
Vol Ratio (20d)0.72x
52W Range
48.2082% of range83.25
52W High83.25 CHF
52W Low48.20 CHF
Profitability
Gross Margin28.74%
EBITDA Margin30.32%
Profit Margin21.41%
Oper. Margin26.27%
ROE10.20%
ROA7.06%
Revenue Growth4.70%
Earnings Growth16.60%
Balance Sheet
Debt/Equity4.13
Current Ratio1.79
Quick Ratio0.54
Book Value/Sh19.46 CHF
Cash/Share0.4140 CHF
Dividends
Fwd Div Rate0.9000 CHF
Trail. Div Rate0.9000 CHF
Div. Yield1.19%
5Y Avg Yield1.03%
Payout Ratio42.93%
Ex-Div DateMay 4, 2026
Pay DateMay 7, 2025
Splits
Last Split5:1
Split DateMay 5, 2022
Ownership
Shares Out.74.94M
Float74.74M
Insiders0.25%
Institutions82.16%
Analyst Consensus
Rating2.2 (Buy)
Target (Mean)78.80 CHF
Target Range46.00 CHF – 110.00 CHF
# Analysts10
Company
Market Cap5.76B CHF
Enterprise Value5.68B CHF
Revenue (TTM)695.07M CHF
Gross Profit199.73M CHF
Net Income (TTM)148.79M CHF
Revenue/Share9.272 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees2.1K
Last Price76.80 CHF
CountryCH
SectorHealthcare
IndustryBiotechnology
ISIN—